EGFR and chronic myelogenous leukemia, BCR-ABL1 positive: This deletion polymorphism occurs naturally in 12.9% of East-Asian individuals and is observed in some individuals with chronic myeloid leukemia (CML) or epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) that conferred resistance to tyrosine kinase inhibitors such as gefitinib [31, 32].